

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			ATTY DOCKET NO. <b>01997.001800</b>		APPLICATION NO. <b>10/808,522</b>		
			APPLICANT <b>WEI LIU ET AL.</b>				
			FILING DATE <b>March 25, 2004</b>		GROUP <b>1645</b>		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		<b>6,506,559</b>		<b>Fire et al.</b>			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
<i>QJ</i>	WO	<b>01/38503 A2</b>	<b>05/31/01</b>	<b>PCT</b>			<b>ENGLISH</b>
<i>AV</i>	WO	<b>02/053749 A2</b>	<b>07/11/02</b>	<b>PCT</b>			<b>ENGLISH</b>
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Altafaj, X. et al., "Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1a (minibrain), a murine model of Down's syndrome," <i>Hum. Mol. Genet.</i> , Vol. 10, pp.1915-23 (2001)					
		Arts, G-J. et al., "Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene Function," <i>Genome Res.</i> , Vol. 13, pp. 2325-32 (2003).					
		Bairoch, A. and Claverie, J-M., "Sequence patterns in protein kinases," <i>Nature</i> , Vol. 331, p.22 (Jan. 1988)					
		Bass, B.L., "RNA Interference: The Short Answer," <i>Nature</i> , Vol. 411, No. 6836, pp. 428-29 (May 2001).					
		Bockamp, E. et al., "Of Mice and Models: Improved Animal Models for Biomedical Research," <i>Physiol. Genomics</i> , Vol. 11, No. 3, pp. 115-32 (Dec. 2002).					
		Bolse, L.H. et al., "bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death," <i>Cell</i> , Vol. 74, pp. 597-608 (Aug. 1993)					
		Charbonneau, H. and Tonks, N.K., "1002 protein phosphatases?", <i>Annu. Rev. Cell Biol.</i> , Vol. 8, pp.463-93 (1992)					
		D'Orazi, G. et al., "Homeodomain-Interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis," <i>Nat. Cell Biol.</i> , Vol. 4, pp. 11-19 (Jan. 2002)					
		Duman, R.S. et al., "Neural plasticity to stress and antidepressant treatment," <i>Biol. Psychiatry</i> , Vol 46, pp.1181-91 (1999)					
		Dumas, J., "Growth factor receptor kinase inhibitors: recent progress and clinical impact," <i>Curr. Opin. Drug Discov. Devel.</i> , Vol. 4, pp.378-89 (2001)					
		Egan, S.E. and Weinberg, R.A., "The pathway to signal achievement," <i>Nature</i> , Vol. 365, pp.781-83 (Oct. 1993)					
		Elbashir, S.M. et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," <i>Nature</i> , Vol. 411, No. 6836, pp. 494-98 (May 2001).					
		Elbashir, S.M. et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila melanogaster</i> Embryo Lysate," <i>EMBO J.</i> , Vol. 20, No. 23, pp. 6877-88 (Dec. 2001).					
		Gage, F.H., "Neurogenesis in the adult brain," <i>J. Neurosci.</i> , Vol. 22, pp.612-13 (Feb. 2002)					
EXAMINER		PRIMARY EXAMINER		DATE CONSIDERED			
				<i>JUL 18 2006</i>			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)			ATTY DOCKET NO. <b>01997.001800</b>	APPLICATION NO. <b>10/808,522</b>			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			APPLICANT <b>WEI LIU ET AL.</b>				
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			FILING DATE <b>March 25, 2004</b>		GROUP <b>1645</b>		
NOV 17 2004 PATENT & TRADEMARK OFFICE							
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Galderisi, U. et al., "Antisense Oligonucleotides as Therapeutic Agents," <i>J. Cell Physiol.</i> , Vol. 181, No. 2, pp. 251-57 (Nov. 1999).						
	Gao, G. et al., "Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase," <i>J. Biol. Chem.</i> , Vol. 271, pp. 8675-81 (Apr. 1996)						
	Haribabu, B. et al., "Human calcium-calmodulin dependent protein kinase I: cDNA cloning, domain structure and activation by phosphorylation at threonine-177 by calcium-calmodulin dependent protein kinase I kinase," <i>EMBO J.</i> , Vol. 14, pp. 3679-86 (1995)						
	Heasman, J., "Morpholino Oligos: Making Sense of Antisense?," <i>Dev. Biol.</i> , Vol. 243, No. 2, pp. 209-14 (Mar. 2002).						
	Himpel, S. et al., "Specificity determinants of substrate recognition by the protein kinase DYRK1A," <i>J. Biol. Chem.</i> , Vol. 275:2431-38 (Jan. 2000)						
	Hofmann, T.G. et al., "Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2," <i>Nat. Cell Biol.</i> , Vol. 4, pp. 1-10 (Jan. 2002) (plus one page supplementary information).						
	Hofmann, T.G. et al., "Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34," <i>Biochimie</i> , Vol. 82: 1123-27 (2000)						
	Hunter, T., "The role of tyrosine phosphorylation in cell growth and disease," <i>Harvey Lect.</i> , Vol. 94, pp. 81-119 (1998-99)						
	Jacobs, B.L. et al., "Adult brain neurogenesis and psychiatry: a novel theory of depression," <i>Mol. Psychiatry</i> , Vol. 5, pp.262-69 (2000)						
	Kaur, G. et al., "Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275," <i>J. Natl. Cancer Inst.</i> , Vol. 84, pp.1736-40, (1992)						
	Kim, Y.H. et al., "Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors," <i>J. Biol. Chem.</i> , Vol. 273, pp. 25875-79 (Oct. 1998)						
	Levitzki, A. and Gazit, A., "Tyrosine kinase inhibition: an approach to drug development," <i>Science</i> , Vol. 267, pp. 1782-88 (Mar. 1995)						
	Li, B. et al., "prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas," <i>J. Biol. Chem.</i> , Vol. 271, pp.19402-08 (Aug. 1996)						
EXAMINER			SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER		DATE CONSIDERED		JUL 18 2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			ATTY DOCKET NO. <b>01997.001800</b>		APPLICATION NO. <b>10/808,522</b>		
			APPLICANT <b>WEI LIU ET AL.</b>				
			FILING DATE <b>March 25, 2004</b>		GROUP <b>1645</b>		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
<p><i>JS</i></p> <p>Manning, G. et al., "The Protein Kinase Complement of the Human Genome," <i>Science</i>, Vol. 298, pp. 1912-16, 1933-34 (Dec. 2002).</p> <p>Micklefield, J., "Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications," <i>Curr. Med. Chem.</i>, Vol. 8, No. 10, pp. 1157-79 (Aug. 2001).</p> <p>Paddison, P.J. et al., "Stable Suppression of Gene Expression by RNAi in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i>, Vol. 99, pp. 1443-48 (Feb. 2002)</p> <p>Reynolds, A. et al., "Rational siRNA design for RNA Interference," <i>Nat. Biotechnol.</i>, Vol. 22, 326-30 (Mar. 2004)</p> <p>Rochat-Steiner, V. et al., "FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation," <i>J. Exp. Med.</i>, Vol. 192, pp. 1165-74 (Oct. 2000)</p> <p>Sioud, M., "Nucleic Acid Enzymes as a Novel Generation of Anti-gene agents," <i>Curr. Mol. Med.</i>, Vol. 1, pp. 575-88 (2001)</p> <p>Song, E. et al., "RNA interference Targeting Fas Protects Mice from Fulminant Hepatitis," <i>Nat. Med.</i>, Vol. 9, pp. 347-51 (Mar. 2003)</p> <p>Sridhar, R. et al., "Protein kinases as therapeutic targets," <i>Pharm. Res.</i>, Vol. 17, pp. 1345-53 (2000)</p> <p>Sui, G. et al., "A DNA Vector-based RNAi Technology to Suppress Gene Expression in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i>, Vol. 99, pp. 5515-20 (Apr. 2002)</p> <p>Tejedor, F. et al., "minibrain: a new protein kinase family involved in postembryonic neurogenesis in <i>Drosophila</i>," <i>Neuron</i>, Vol. 14, pp. 287-301 (Feb. 1995)</p> <p>Turek, T.C. et al., "Development and validation of a competitive AKT serine/threonine kinase fluorescence polarization assay using a product-specific anti-phospho-serine antibody," <i>Anal. Biochem.</i>, Vol. 299, pp. 45-53 (2001)</p> <p>Wolfer, D.P. et al., "Knockout mice: simple solutions to the problems of genetic background and flanking genes," <i>Trends Neurosci.</i>, Vol. 25, pp. 336-40 (Jul. 2002)</p> <p>Xia, Z. et al., "Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism," <i>J. Neurosci.</i>, Vol. 16, pp. 5425-36 (Sep. 1996)</p> <p>Yu, J-Y. et al., "RNA Interference by Expression of Short-Interfering RNAs and Hairpin RNAs in Mammalian Cells," <i>Proc. Natl. Acad. Sci. USA</i>, Vol. 99, pp. 6047-52 (Apr. 2002)</p>							
EXAMINER SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER			DATE CONSIDERED		JUL 18 2006		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 3

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE CITATIONS CITED BY APPLICANT(S) (Use several sheets if necessary)			ATTY DOCKET NO. <b>01997.001800</b>	APPLICATION NO. <b>10/808,522</b>			
			APPLICANT <b>WEI LIU ET AL.</b>				
			FILING DATE <b>March 25, 2004</b>	GROUP <b>1645</b>			
U.S. PATENT DOCUMENTS							
EXAMINER INITIALS <i>SS</i>	TRADEMARK OFFICE <i>PTO</i>	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
<i>SS</i>	WO	DOCUMENT NUMBER 02/083709A	DATE 10/24/02	COUNTRY PCT	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
<i>SS</i>	WO	2004/006838A	01/22/04	PCT			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>SS</i>		DATABASE EMBL Human genomic sequence of clone CTC-492K19, XP002293537, Database accession No. AC010271 (Sept. 17, 1999)(2 pgs.)					
		DATABASE EMBL Mouse genomic sequence of clone RP23-359H6, XP002293536, Database accession No. AC073767 (July 6, 2000)(52 pgs.)					
		DATABASE UNIPROT 'Online' HIPK4, XP002293538, Database accession No. Q8NE63 (Oct. 1, 2002)(2 pgs.)					
		DATABASE UNIPROT 'Online' Serine-threonine kinase from macaca, XP002293535, Database accession No. Q8WP28 (Mar. 1, 2002)(2 pgs.)					
		DATABASE OMIM NCBI; Review concerning HIPK1, XP002293539, Database accession No. 608003 (2 pgs.)					
<i>SS</i>		DATABASE OMIM NCBI; Review concerning HIPK2, XP002293540, Database accession No. 606868 (2 pgs.)					
EXAMINER <b>SHERIDAN SWOPE, PH.D.</b> PRIMARY EXAMINER			DATE CONSIDERED		<b>JUL 18 2006</b>		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with +MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.